

Ryuichi Morishita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6632870/publications.pdf>

Version: 2024-02-01

98
papers

3,905
citations

117625

34
h-index

128289

60
g-index

108
all docs

108
docs citations

108
times ranked

4873
citing authors

#	ARTICLE	IF	CITATIONS
1	Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. <i>Hypertension Research</i> , 2022, 45, 61-65.	2.7	8
2	A novel chronic dural port platform for continuous collection of cerebrospinal fluid and intrathecal drug delivery in free-moving mice. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 31.	5.0	4
3	Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF- κ B Ligand Peptide in Mice. <i>ImmunoHorizons</i> , 2021, 5, 438-447.	1.8	5
4	Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey. <i>Scientific Reports</i> , 2021, 11, 11472.	3.3	4
5	Therapeutic vaccine for chronic diseases after the COVID-19 Era. <i>Hypertension Research</i> , 2021, 44, 1047-1053.	2.7	7
6	Prevention of vascular dementia via immunotherapeutic blockade of renin-angiotensin system in a rat model. <i>Brain Research</i> , 2021, 1772, 147667.	2.2	4
7	Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults. <i>Translational and Regulatory Sciences</i> , 2021, .	0.2	0
8	Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. <i>Nature Aging</i> , 2021, 1, 1117-1126.	11.6	87
9	Roles of vascular risk factors in the pathogenesis of dementia. <i>Hypertension Research</i> , 2020, 43, 162-167.	2.7	33
10	Increased levels of A β 242 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes. <i>FASEB Journal</i> , 2020, 34, 2425-2435.	0.5	15
11	Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model. <i>Hypertension</i> , 2020, 76, 1879-1888.	2.7	7
12	Progress of Gene Therapy in Cardiovascular Disease. <i>Hypertension</i> , 2020, 76, 1038-1044.	2.7	16
13	The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. <i>Nature Communications</i> , 2020, 11, 2482.	12.8	64
14	Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. <i>Current Gene Therapy</i> , 2020, 20, 25-35.	2.0	14
15	Future Directions of Therapeutic Vaccines for Chronic Diseases. <i>Circulation Journal</i> , 2020, 84, 1895-1902.	1.6	5
16	Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm. <i>Annals of Vascular Diseases</i> , 2019, 12, 137-146.	0.5	9
17	Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis. <i>Scientific Reports</i> , 2019, 9, 15434.	3.3	10
18	Novel Method for Rapid Assessment of Cognitive Impairment Using High-Performance Eye-Tracking Technology. <i>Scientific Reports</i> , 2019, 9, 12932.	3.3	73

#	ARTICLE	IF	CITATIONS
19	Dysfunctional high density lipoprotein failed to rescue the function of oxidized low density lipoprotein-treated endothelial progenitor cells: a novel index for the prediction of HDL functionality. <i>Translational Research</i> , 2019, 205, 17-32.	5.0	13
20	Prevention of Asthma Exacerbation in a Mouse Model by Simultaneous Inhibition of NF- κ B and STAT6 Activation Using a Chimeric Decoy Strategy. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 10, 159-169.	5.1	17
21	Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice. <i>Current Hypertension Reports</i> , 2018, 20, 22.	3.5	9
22	Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke. <i>Scientific Reports</i> , 2018, 8, 17770.	3.3	16
23	Recent Advances in Therapeutic Vaccines to Treat Hypertension. <i>Hypertension</i> , 2018, 72, 1031-1036.	2.7	20
24	Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. <i>Hypertension</i> , 2018, 72, 1355-1364.	2.7	35
25	Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	8
26	Source of Chronic Inflammation in Aging. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 12.	2.4	267
27	Transplantation of lineage-negative stem cells in pterygopalatine artery ligation induced retinal ischemiaâ€“reperfusion injury in mice. <i>Molecular and Cellular Biochemistry</i> , 2017, 429, 123-136.	3.1	6
28	A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. <i>Scientific Reports</i> , 2017, 7, 43920.	3.3	25
29	Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. <i>Stroke</i> , 2017, 48, 1362-1368.	2.0	29
30	Angiotensin Receptor Blocker Protects Alzheimerâ€™s Disease Brain From Ischemic Insult. <i>American Journal of Hypertension</i> , 2017, 30, 110-111.	2.0	1
31	Inhibition of Aneurysm Progression by Direct Renin Inhibition in a Rabbit Model. <i>Hypertension</i> , 2017, 70, 1201-1209.	2.7	12
32	Influence of periostin-positive cell-specific Klf5 deletion on aortic thickening in DOCA-salt hypertensive mice. <i>Hypertension Research</i> , 2016, 39, 764-768.	2.7	3
33	A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke. <i>Scientific Reports</i> , 2016, 6, 38062.	3.3	28
34	Therapeutic effect of intraâ€“articular injection of ribbonâ€“type decoy oligonucleotides for hypoxia inducible factorâ€“1 on joint contracture in an immobilized knee animal model. <i>Journal of Gene Medicine</i> , 2016, 18, 180-192.	2.8	18
35	Different roles played by periostin splice variants in retinal neovascularization. <i>Experimental Eye Research</i> , 2016, 153, 133-140.	2.6	18
36	Selective Blockade of Periostin Exon 17 Preserves Cardiac Performance in Acute Myocardial Infarction. <i>Hypertension</i> , 2016, 67, 356-361.	2.7	56

#	ARTICLE	IF	CITATIONS
37	Current therapies and investigational drugs for peripheral arterial disease. <i>Hypertension Research</i> , 2016, 39, 183-191.	2.7	40
38	Low alpha-synuclein levels in the blood are associated with insulin resistance. <i>Scientific Reports</i> , 2015, 5, 12081.	3.3	36
39	The roles of lipid and glucose metabolism in modulation of β -amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 199.	3.4	134
40	The Biphasic Effects of Oxidized-Low Density Lipoprotein on the Vasculogenic Function of Endothelial Progenitor Cells. <i>PLoS ONE</i> , 2015, 10, e0123971.	2.5	22
41	Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2015, 66, 167-174.	2.7	37
42	Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse. <i>Hypertension Research</i> , 2015, 38, 382-393.	2.7	12
43	Teneligliptin: expectations for its pleiotropic action. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 417-426.	1.8	35
44	Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. <i>Geriatrics and Gerontology International</i> , 2015, 15, 1064-1072.	1.5	19
45	New era in gene therapy: end of the beginning. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 309-310.	3.1	1
46	Modeling transient retinal ischemia in mouse by ligation of pterygopalatine artery. <i>Annals of Neurosciences</i> , 2015, 22, 222-5.	1.7	10
47	Ultrasound attacks Alzheimer's disease?. <i>Annals of Translational Medicine</i> , 2015, 3, 276.	1.7	0
48	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 71.	3.4	43
49	Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 171.	3.4	173
50	Peptide Vaccines for Hypertension and Diabetes Mellitus. <i>Vaccines</i> , 2014, 2, 832-840.	4.4	6
51	OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8191-8196.	7.1	93
52	Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. <i>Hypertension Research</i> , 2014, 37, 500-506.	2.7	32
53	Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor- κ B Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 787-796.	3.9	13
54	Brain Alterations and Clinical Symptoms of Dementia in Diabetes: A β /Tau-Dependent and Independent Mechanisms. <i>Frontiers in Endocrinology</i> , 2014, 5, 143.	3.5	52

#	ARTICLE	IF	CITATIONS
55	Long-term expression of periostin during the chronic stage of ischemic stroke in mice. <i>Hypertension Research</i> , 2014, 37, 494-499.	2.7	15
56	Beperminogene perplasmid for the treatment of critical limb ischemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1145-1156.	1.5	17
57	Therapeutic vaccine against DPP4 improves glucose metabolism in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1256-63.	7.1	39
58	The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. <i>Hypertension Research</i> , 2014, 37, 629-635.	2.7	34
59	Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice. <i>PLoS ONE</i> , 2013, 8, e60493.	2.5	44
60	Development of Oral Formulation Technology for Nucleic Acid Drug by Using PLGA Nanoparticles as DDS Carriers. <i>Journal of the Society of Powder Technology, Japan</i> , 2013, 50, 513-518.	0.1	3
61	Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study. <i>Current Vascular Pharmacology</i> , 2012, 10, 178-186.	1.7	5
62	Eight-Year Follow-Up of an Initial Case with NF- κ B Decoy Oligodeoxynucleotide Transfection After Coronary Stent Implantation. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 40-42.	0.5	1
63	Links Between Hypertension and Osteoporosis: Benidipine Ameliorates Osteoporosis in Ovariectomized Hypertensive Rats Through Promotion of Osteoblast Proliferation and Inhibition of Osteoclast Differentiation. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 274-280.	2.0	5
64	Systemic Administration of Ribbon-type Decoy Oligodeoxynucleotide Against Nuclear Factor κ B and Ets Prevents Abdominal Aortic Aneurysm in Rat Model. <i>Molecular Therapy</i> , 2011, 19, 181-187.	8.2	33
65	How to evaluate real-world medicine in a Japanese population: important lessons from the JIKEI, CASE-J, KYOTO and VART studies. <i>Hypertension Research</i> , 2011, 34, 33-35.	2.7	0
66	Polymorphism of myospryn is associated with left ventricular diastolic dysfunction. <i>Anti-aging Medicine</i> , 2008, 5, 49-52.	0.7	0
67	Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. <i>International Journal of Molecular Medicine</i> , 2008, 22, 703-8.	4.0	46
68	Regression of Abdominal Aortic Aneurysms by Simultaneous Inhibition of Nuclear Factor κ B and Ets in a Rabbit Model. <i>Circulation Research</i> , 2007, 101, 1175-1184.	4.5	66
69	Does gene therapy become pharmacotherapy?. <i>Experimental Physiology</i> , 2005, 90, 307-313.	2.0	12
70	A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis. <i>Atherosclerosis Supplements</i> , 2005, 6, 41-46.	1.2	44
71	Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease. <i>Hypertension</i> , 2004, 44, 203-209.	2.7	208
72	Molecular therapy to inhibit NF κ B activation by transcription factor decoy oligonucleotides. <i>Current Opinion in Pharmacology</i> , 2004, 4, 139-146.	3.5	85

#	ARTICLE	IF	CITATIONS
73	Initial Clinical Cases of the Use of a NF- κ B Decoy at the Site of Coronary Stenting for the Prevention of Restenosis. <i>Circulation Journal</i> , 2004, 68, 270-271.	1.6	33
74	Perspective in Progress of Cardiovascular Gene Therapy. <i>Journal of Pharmacological Sciences</i> , 2004, 95, 1-8.	2.5	34
75	Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF). <i>Current Gene Therapy</i> , 2004, 4, 199-206.	2.0	110
76	Therapeutic Potential of Oligonucleotide-Based Therapy in Cardiovascular Disease. <i>BioDrugs</i> , 2003, 17, 383-389.	4.6	9
77	Angiogenesis and Its Therapeutic Implication 4. <i>Cardiovascular Disease and Angiogenesis. Internal Medicine</i> , 2003, 42, 301-302.	0.7	1
78	Preface: Transcription Factor as Molecular Targets: Is Transcription Factor Decoy a Novel Drug ? [Hot topic: Transcription Factor as Molecular Targets (Guest Editor: Ryuichi Morishita)]. <i>Current Drug Targets</i> , 2003, 4, i-i.	2.1	0
79	Recent Progress in Gene Therapy for Cardiovascular Disease.. <i>Circulation Journal</i> , 2002, 66, 1077-1086.	1.6	29
80	Hepatocyte Growth Factor as Cardiovascular Hormone: Role of HGF in the Pathogenesis of Cardiovascular Disease. <i>Endocrine Journal</i> , 2002, 49, 273-284.	1.6	61
81	[36] HVJ (hemagglutinating virus of Japan; Sendai virus)-liposome method. <i>Methods in Enzymology</i> , 2002, 346, 619-627.	1.0	2
82	HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque. <i>Current Drug Targets</i> , 2002, 3, 379-385.	2.1	13
83	Gene therapy for neurological diseases(Plenary Session 3 Application of gene diagnosis and gene) Tj ETQq1 1 0.784314 rgBT ₀ Overlock	0.0	0
84	Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model. <i>Hypertension</i> , 2001, 37, 270-274.	2.7	37
85	Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model. <i>Circulation</i> , 2001, 104, 2344-2350.	1.6	184
86	Contribution of Bcl-2, but Not Bcl-xL and Bax, to Antiapoptotic Actions of Hepatocyte Growth Factor in Hypoxia-Conditioned Human Endothelial Cells. <i>Hypertension</i> , 2001, 37, 1341-1348.	2.7	72
87	Mitogenic and Antiapoptotic Actions of Hepatocyte Growth Factor Through ERK, STAT3, and Akt in Endothelial Cells. <i>Hypertension</i> , 2001, 37, 581-586.	2.7	146
88	Ribozyme Oligonucleotides Against Transforming Growth Factor- β Inhibited Neointimal Formation After Vascular Injury in Rat Model. <i>Circulation</i> , 2000, 102, 1308-1314.	1.6	97
89	Transfection of Antisense <i>p53</i> Tumor Suppressor Gene Oligodeoxynucleotides Into Rat Carotid Artery Results in Abnormal Growth of Vascular Smooth Muscle Cells. <i>Circulation</i> , 2000, 101, 1447-1452.	1.6	35
90	Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. <i>Circulation</i> , 2000, 102, 246-252.	1.6	182

#	ARTICLE	IF	CITATIONS
91	Adventure of Gene Therapy Into the Brain: A New Era for Cardiovascular Gene Therapy. Circulation Research, 2000, 87, 719-721.	4.5	9
92	Angiotensinogen Gene-Activating Elements Regulate Blood Pressure in the Brain. Circulation Research, 1999, 85, 257-263.	4.5	20
93	Therapeutic Angiogenesis Induced by Human Recombinant Hepatocyte Growth Factor in Rabbit Hind Limb Ischemia Model as Cytokine Supplement Therapy. Hypertension, 1999, 33, 1379-1384.	2.7	262
94	Present and Future in the genetherapy for cardiovascular disease. The Journal of Japan Atherosclerosis Society, 1999, 26, 263-268.	0.0	0
95	Inhibition of Growth of Human Vascular Smooth Muscle Cells by Overexpression of p21 Gene Through Induction of Apoptosis. Hypertension, 1998, 31, 493-498.	2.7	42
96	INHIBITION OF NEOINTIMAL FORMATION AND INCREASED LOCAL VASCULAR HEPATOCYTE GROWTH FACTOR (HGF) PRODUCTION IN BALLOON INJURED ARTERIES BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR. International Heart Journal, 1997, 38, 577-577.	0.6	0
97	Role of Transcriptional cis-Elements, Angiotensinogen Gene-Activating Elements, of Angiotensinogen Gene in Blood Pressure Regulation. Hypertension, 1996, 27, 502-507.	2.7	48
98	A Vascular Modulator, Hepatocyte Growth Factor, Is Associated With Systolic Pressure. Hypertension, 1996, 28, 409-413.	2.7	113